HB-2121
Phase 1Small molecule
HB-2121 is one of 12 small molecule programs targeting Celiac Disease. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Celiac Disease
#DrugCompanyPhaseTrials
1Advil
KKenvue Brands
Approved
Tylenol
KKenvue Brands
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Sporanox
SSebela Pharmaceuticals Development LLC
Approved
VIOKACE
DDigestive Care, Inc.
Approved
DONQ52
RochePhase 2
Xifaxan
SSalix
Preclinical
Hepatitis B Vaccine
SanofiPreclinical
ZED1227
DDr. Falk Pharma GmbH
Phase 2
FB102
FForte Biosciences, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HB-2121. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- NNielsen Fernandez-Becker